malaria
mosquitoborn
parasit
diseas
caus
member
plasmodium
genu
result
least
death
worldwid
current
attempt
elimin
diseas
human
popul
attempt
vector
control
diagnosi
develop
pharmaceut
success
reduc
number
case
howev
major
miss
piec
elimin
campaign
effect
vaccin
candid
current
success
vaccin
candid
rt
protect
children
subsaharan
africa
vulner
popul
goal
malaria
elimin
weak
rt
necessit
develop
new
success
vaccin
candid
one
appeal
yet
elus
malaria
vaccin
candid
one
target
asexu
blood
stage
clinic
stage
diseas
issu
antigen
polymorph
lack
mhc
molecul
erythrocyt
speed
erythrocyt
infect
hamper
develop
asexu
blood
stage
vaccin
mani
differ
antigen
candid
technic
approach
attempt
littl
success
problem
led
search
new
potenti
blood
stage
antigen
use
differ
screen
mechan
includ
bioinformat
approach
one
bioinformat
approach
coiledcoil
domain
present
asexu
blood
stage
target
coiledcoil
domain
common
oligomer
domain
protein
known
characterist
heptad
repeat
stabil
make
excel
choic
vaccin
develop
one
interest
target
identifi
screen
show
complet
conserv
field
isol
amino
acid
sequenc
contain
amino
acid
trophozoit
export
protein
howev
abl
activ
peripher
blood
mononuclear
cell
pbmc
semiimmun
individu
lead
fear
would
offer
broad
protect
vaccin
divers
popul
lead
screen
protein
identif
ntermin
portion
protein
region
predict
intrins
unstructur
initi
screen
demonstr
peopl
live
endem
area
antibodi
immunogen
small
mammal
model
antibodi
rais
capabl
inhibit
p
falciparum
antibodydepend
cellular
inhibit
parasitegrowth
assay
current
good
immunogen
result
obtain
phase
ia
ib
clinic
trial
combin
adjuv
glase
alhydrogel
clinicaltrialsgov
manuscript
prepar
subunit
vaccin
base
sole
recombin
protein
gener
weakli
immunogen
like
success
vaccin
human
effect
vaccin
import
consider
deliveri
system
sever
recent
effect
vaccin
candid
base
particul
deliveri
system
abl
repetit
express
antigen
one
promis
deliveri
system
selfassembl
protein
nanoparticl
sapn
sapn
monom
subunit
oligomer
form
nanoparticl
contain
two
coiledcoil
domain
held
togeth
linker
antigen
bcell
epitop
engin
either
n
c
termin
end
gene
encod
monom
way
tcell
epitop
ad
core
lead
vaccin
candid
abl
activ
humor
cellular
branch
immun
system
sapn
show
great
promis
vaccin
design
mani
sapnbas
malaria
vaccin
previous
develop
laboratori
normal
sequenc
amino
acid
form
pentamer
trimer
oligomer
domain
de
novo
design
sequenc
homolog
human
protein
minim
possibl
induc
immun
respons
could
detriment
host
receiv
vaccin
detail
unusu
step
develop
sapn
vaccin
candid
use
parasit
nativ
coiledcoil
sequenc
epitop
protein
form
part
core
oligomer
domain
combin
intrins
unstructur
epitop
vaccin
candid
immunogen
murin
model
induc
antibodi
recogn
antigen
sera
seroposit
individu
burkina
faso
malaria
endem
region
kkrnveeelhslrknyniineeieeit
hnnneknisydknlvkqendnkdeargndnmcgnydihnergemldkgksysgdekintsdn
akscsgdekvitsdngksydyvkneseeqeekenmlnnkkr
krnveeelhslrknyniineeieeitkefekkqeqvdemilqiknkel
kefekkqeqvdemilqiknkel
singl
antigen
present
sapn
scaffold
synthes
solidphas
fmoc
chemistri
use
appli
biosystem
synthes
foster
citi
ca
previous
describ
peptid
puriti
assess
analyt
hplc
mass
spectrometri
malditof
appli
biosystem
higher
reagent
use
purchas
fluka
buch
switzerland
novabiochem
switzerland
mghhhhhhasgsweewnakwdewirawvawraawekwkddwaywtltwkygelysklrnveeelhslrknyniineeieeitkefekkqeqvdemiiqiknkel
mghhhhhhaslidynkaalskfkergswqtwnakwdvwsndwnawrarwqawvddwaywtltwkygelysklrnveeelhslrknyniineeieeitkefekkqeqvdemiiqiknkel
mghhhhhhasgswqtwnakwdvwsndwnawradwqawvddwaywtltwkygelysklaeierrveaneraleelaqfvralsmqaaelerrieeiarghnnneknisydknlvkqendnkdeargndnmsgnydihnergemldkgksysgdekintsdnaksssgdekvitsdngksydyvkneseeqeekenmlnnkkr
mghhhhhhasyyiphqsslpgswqtwnakwdvwsndwnawradwqawvddwaywtltwkygelysklaeierrveaneraleelaqfvralsmqaaelseditkyfrhilyisfyfilvnrarghnnneknisydknlvkqendnkdeargndnmsgnydihnergemldkgksysgdekintsdnaksssgdekvitsdngksydyvkneseeqeekenmlnnkkr
sapncombo
mgdhhhhhhhhhhaahaahaahaahaaaarghnnneknisydknlvkqendnkdeargndnmcgnydihnergemldkgksysgdekintsdnakscsgdekvitsdngksydyvkneseeqeekenmlnnkkrsasgsakfvaawtlkaaasgsweewnakwdewrndqndwredwqawrddwaywtltwrygelysrlarierrveelrrllqlirhenrmvlqfvralsmqarrlesklrnveeelhslrknyniineeieeitkefekkqeqvdemilqiknkel
codon
optim
gene
e
coli
synthes
genescript
usa
inc
piscatway
nj
contain
sequenc
construct
sapncombo
gene
clone
ppept
vector
result
construct
transform
tuner
compet
cell
millipor
billerica
protein
express
carri
lb
broth
fisherbioreag
pittsburgh
pa
briefli
starter
cultur
grown
h
inocul
lb
grown
cultur
induc
mm
iptg
fisherbioreag
pittsburgh
pa
cultur
grown
h
pellet
g
store
use
cell
pellet
thaw
ice
resuspend
imidazol
free
buffer
urea
mm
mm
tri
base
mm
tri
phosphin
ph
lyse
sonic
centrifug
g
min
clarifi
lysat
purif
carri
ge
healthcar
piscataway
nj
use
ml
histrap
hp
column
ge
healthcar
piscataway
nj
briefli
column
equilibr
bind
buffer
urea
mm
mm
imidazol
mm
tri
base
mm
tri
phosphin
ph
lysat
inject
wash
five
column
volum
bind
buffer
column
wash
column
volum
high
phosphat
buffer
urea
mm
mm
tri
base
mm
tri
phosphin
ph
bind
buffer
isopropanol
wash
isopropanol
mm
tri
base
ph
remov
lp
final
imidazol
free
buffer
protein
elut
use
imidazol
gradient
result
recov
protein
verifi
sdspage
dialyz
overnight
prerefold
buffer
urea
mm
nacl
mm
tri
glycerol
tri
phosphin
ph
sapn
allow
refold
stepwis
manner
slowli
remov
urea
tri
phosphin
result
refold
sapn
mm
tri
base
glycerol
ph
refold
monitor
dynam
light
scatter
use
malvern
zetas
nano
malvern
worcestershir
uk
equip
laser
hydrodynam
diamet
determin
sampl
run
time
averag
result
taken
mgml
sampl
adsorb
onto
carbon
coat
grid
electron
microscopi
scienc
inc
hatfield
pa
subject
glow
discharg
wash
distil
water
three
time
neg
stain
uranyl
acet
electron
microscopi
scienc
inc
hatfield
pa
electron
micrograph
taken
fei
tecnai
transmiss
electron
microscop
human
plasma
collect
malaria
transmiss
season
adult
donor
live
burkina
faso
plasma
swiss
naiv
donor
malaria
histori
pool
use
neg
control
blood
taken
venipunctur
tube
contain
edta
accord
ethic
clearanc
balbc
mice
immun
np
pb
base
tail
three
time
week
interv
mice
individu
bled
day
immun
tail
vein
correspond
sera
store
mous
studi
conduct
accord
protocol
vd
approv
state
committe
anim
research
preval
human
titer
mice
determin
elisa
antigen
dilut
pb
use
coat
elisa
plate
antigen
concentr
coat
flat
plate
bd
bioscienc
allschwil
switzerland
peptid
longer
residu
peptid
shorter
equal
residu
previous
describ
secondari
ab
sheep
goat
antihuman
mous
polyval
immunoglobulin
g
ap
sigmaaldrich
st
loui
mo
use
dilut
indic
provid
pbst
plu
milk
preval
determin
plasma
dilut
preval
posit
od
sampl
control
titer
defin
last
dilut
od
sampl
control
elisa
plate
coat
appropri
peptid
describ
wash
block
serum
sampl
appropri
dilut
maximum
od
determin
elisa
preincub
appropri
compet
synthet
peptid
increas
concentr
min
room
temperatur
antibodypeptid
mixtur
ad
appropri
well
incub
h
room
temperatur
humid
chamber
elisa
complet
describ
alreadi
shown
sapn
effect
carrier
preerythrocyt
malaria
antigen
circumsporozoit
protein
csp
believ
sapn
technolog
excel
platform
develop
malaria
vaccin
candid
base
previous
studi
epitop
protein
prototyp
sapn
design
consist
pentamer
coiledcoil
oligomer
domain
link
trimer
coiledcoil
oligomer
domain
found
predict
trimer
coiledcoil
within
residu
howev
accord
coiledcoil
predict
program
pcoil
coiledcoil
sequenc
extend
span
least
residu
fig
prompt
us
engin
longer
sequenc
residu
contain
ntermin
ctermin
sequenc
whole
extend
coiledcoil
stretch
call
remark
ctermin
fragment
highli
conserv
among
mani
plasmodium
speci
fig
thu
potenti
provid
crossprotect
immun
respons
sapn
uniqu
design
allow
stabli
display
nativ
coiledcoil
conform
increas
immunogen
specif
thu
creat
effect
vaccin
candid
approach
previous
taken
trimer
coiledcoil
epitop
sar
spike
protein
intrins
unstructur
epitop
conform
restrict
domain
ridg
shape
pentamer
coiledcoil
domain
selfassembl
four
pentamer
coiledcoil
domain
trimer
coiledcoil
domain
selfassembl
two
trimer
coiledcoil
domain
satisfi
assembl
requir
monom
selfassembl
structur
known
least
common
multipl
unit
lcm
standard
icosahedr
structur
four
lcm
selfassembl
full
sapn
structur
mean
monom
make
sapn
howev
recent
biophys
studi
combin
analysi
use
viral
tile
theori
shown
sapn
possibl
also
assembl
higher
order
assembl
contain
multipl
chain
per
particl
sapn
predict
contain
copi
multipl
thereof
epitop
fig
indic
effect
repetit
display
epitop
known
result
effect
immun
respons
anoth
advantag
sapn
design
within
sapn
core
univers
thelper
epitop
engin
ideal
lead
effect
immun
respons
epitop
rang
de
novo
design
sequenc
engin
bind
wide
rang
mhc
ii
haplotyp
sequenc
known
infecti
agent
establish
result
strong
thelper
epitop
togeth
repetit
display
epitop
combin
addit
univers
epitop
lead
broadli
immunogen
vaccin
candid
abl
protect
divers
popul
human
p
falciparum
engin
sever
sapn
contain
either
extend
residuelong
trimer
coil
coil
andor
intrins
unstructur
domain
schemat
represent
five
main
construct
sapncombo
shown
fig
correspond
protein
sequenc
list
method
section
comput
model
sapncombo
display
fig
construct
contain
trimer
coiledcoil
epitop
bcell
epitop
lead
sever
aggreg
construct
intrins
unstructur
epitop
form
nice
solubl
nanoparticl
fig
b
character
mm
nacl
mm
phosphat
buffer
ph
glycerol
four
condit
result
satisfactori
nanoparticl
format
construct
character
circular
dichroism
evalu
secondari
structur
mainli
conform
confirm
prior
circular
dichroism
analysi
dl
run
taken
ensur
nanoparticl
within
expect
rang
construct
even
incorpor
addit
featur
three
epitop
string
predict
netmhc
yyiphqssl
elseditki
also
refer
liver
stage
antigen
strain
p
falciparum
allow
format
nice
nanoparticl
fig
reason
combin
problemat
epitop
wellbehav
epitop
one
singl
construct
might
help
format
wellshap
nanoparticl
contain
trimer
coiledcoil
epitop
inde
sapncombo
construct
epitop
structur
biophys
wellbehav
fig
thu
construct
would
abl
combin
deriv
b
cell
epitop
one
singl
protein
chain
form
sapn
sapn
protein
monom
express
tuner
e
coli
purifi
denatur
reduc
condit
use
immobil
metal
chromatographi
result
protein
run
sdspage
gel
verifi
correct
protein
purifi
primari
product
expect
size
rang
kda
sapn
monom
allow
refold
slowli
remov
denatur
reduc
agent
result
product
screen
dl
determin
particl
size
base
upon
dl
read
refold
sapncombo
hydrodynam
diamet
nm
fall
expect
rang
refold
sapn
fig
result
dl
valid
tem
show
sapncombo
taken
particul
structur
fig
result
demonstr
success
express
refold
sapncombo
preval
human
antibodi
respons
specif
sapncombo
construct
singl
compon
determin
measur
percentag
adult
respond
live
burkina
faso
tabl
respons
similar
origin
obtain
individu
compon
mean
od
respect
term
preval
averag
od
immunogen
sapncombo
construct
deliv
pb
buffer
solut
without
addit
adjuv
test
balbc
mice
end
point
titer
obtain
elisa
plate
coat
homolog
construct
tabl
lower
titer
obtain
coat
peptid
fragment
weakli
recogn
sinc
titer
depend
amount
antigen
bound
elisa
plate
structur
integr
better
appreci
contribut
antigen
overal
antibodi
respons
sapncombo
given
determin
inhibit
antibodi
bind
singl
solubl
antigen
total
inhibit
observ
homolog
mode
coat
inhibitori
antigen
data
shown
partial
inhibit
observ
sapncombo
singl
antigen
use
coat
solubl
inhibitor
respect
fig
much
lower
inhibit
observ
line
result
obtain
elisa
individu
antigen
use
coat
plate
compar
tabl
stronger
inhibit
reach
three
antigen
use
togeth
inhibitor
develop
effect
asexu
blood
stage
malari
vaccin
candid
difficult
fraught
problem
appar
gener
effect
candid
new
antigen
choic
well
new
deliveri
technolog
need
develop
demonstr
addit
two
new
promis
bcell
epitop
antigen
sapn
deliveri
system
particular
antigen
current
evalu
clinic
trial
synthet
peptid
clinicaltrialsgov
thu
improv
immunogen
coupl
suitabl
carrier
seem
highli
promis
approach
humor
immun
respons
two
segment
clearli
show
relationship
immunodomin
epitop
versu
less
immunogen
region
promin
expos
portion
ctermin
portion
trimer
coil
coil
ie
induc
stronger
immun
respons
compar
antibodi
product
ntermin
region
tabl
buri
core
sapn
see
fig
remark
correspond
shorter
fragment
recogn
donor
sera
burkina
faso
tabl
sinc
also
highli
conserv
among
mani
differ
plasmodium
speci
fig
welcom
featur
sapn
design
may
induc
crossprotect
among
differ
plasmodium
speci
includ
promin
parasit
speci
p
falciparum
p
vivax
one
major
advantag
sapn
technolog
enabl
addit
two
b
cell
antigen
one
terminu
monom
display
surfac
sapn
addit
tcell
epitop
engin
sapn
core
deliv
antigen
process
machineri
cell
uniqu
design
therefor
allow
inclus
multipl
b
cell
epitop
case
includ
bcell
epitop
establish
immunogen
mice
rabbit
human
manuscript
prepar
combin
varieti
andor
epitop
human
purifi
antibodi
specif
shown
activ
adci
associ
protect
peopl
endem
area
unpublish
result
includ
antigen
like
higher
probabl
induc
protect
antibodi
popul
larg
present
design
particular
advantag
immunogen
without
need
adjuv
summari
new
sapn
repres
new
vaccin
strategi
epitop
express
primarili
asexu
blood
stage
parasit
life
cycl
csp
express
preerythrocyt
stage
csp
base
vaccin
prevent
infect
clinic
symptom
develop
asexu
blood
stage
vaccin
actual
help
deal
prevent
parasitemia
develop
reduc
clinic
symptom
approach
continu
develop
eventu
admix
gener
vaccin
candid
prevent
initi
infect
eventu
prevent
breakthrough
infect
demonstr
sapn
induc
immun
respons
akin
one
seroposit
individu
burkina
faso
sapn
describ
manuscript
repres
key
improv
previou
design
modif
nanoparticl
allow
present
possibl
first
design
sapn
sinc
highli
conserv
might
even
provid
crossprotect
among
differ
plasmodium
speci
confirm
human
clinic
trial
would
allow
develop
robust
vaccin
easi
manufactur
store
deliv
need
popul
vaccin
characterist
remain
holi
grail
vaccin
develop
formul
